Mark J. Ratain to Leukemia, Myeloid, Acute
This is a "connection" page, showing publications Mark J. Ratain has written about Leukemia, Myeloid, Acute.
Connection Strength
0.169
-
Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
Score: 0.082
-
Phase I study of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde-thiosemicarbazone (3-AP) in combination with high dose cytarabine in patients with advanced myeloid leukemia. Invest New Drugs. 2008 Jun; 26(3):233-9.
Score: 0.051
-
Pharmacodynamics and long-term toxicity of etoposide. Cancer Chemother Pharmacol. 1994; 34 Suppl:S64-8.
Score: 0.019
-
Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood. 1992 Apr 01; 79(7):1892-3.
Score: 0.017